BlackRock Inc. purchased a new stake in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,410,053 shares of the company's stock, valued at approximately $63,504,000. BlackRock Inc. owned 3.40% of Aveanna Healthcare as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Aveanna Healthcare by 38.0% in the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company's stock valued at $45,564,000 after acquiring an additional 1,535,351 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Aveanna Healthcare by 49.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,334,374 shares of the company's stock worth $8,593,000 after acquiring an additional 441,707 shares during the last quarter. Segall Bryant & Hamill LLC increased its holdings in shares of Aveanna Healthcare by 425.8% in the 1st quarter. Segall Bryant & Hamill LLC now owns 163,966 shares of the company's stock valued at $1,056,000 after acquiring an additional 132,779 shares during the period. Weiss Asset Management LP acquired a new position in shares of Aveanna Healthcare in the 1st quarter valued at $732,000. Finally, Principal Financial Group Inc. acquired a new stake in Aveanna Healthcare during the 1st quarter worth $895,000. 87.96% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. UBS Group increased their price objective on Aveanna Healthcare from $8.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, August 14th. Stephens raised shares of Aveanna Healthcare from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $10.00 to $11.00 in a report on Friday, May 15th. Barclays increased their price objective on shares of Aveanna Healthcare from $9.50 to $15.00 and gave the company an "overweight" rating in a research note on Friday. Weiss Ratings reissued a "hold (c+)" rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. Finally, Raymond James Financial lifted their price objective on Aveanna Healthcare from $13.00 to $15.00 and gave the company a "strong-buy" rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.50.
Check Out Our Latest Report on AVAH
Aveanna Healthcare Stock Performance
Aveanna Healthcare stock opened at $13.32 on Monday. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 4.47. The stock has a 50 day moving average of $10.18 and a 200-day moving average of $8.11. The stock has a market cap of $2.91 billion, a P/E ratio of 10.83, a price-to-earnings-growth ratio of 0.84 and a beta of 1.90. Aveanna Healthcare Holdings Inc. has a 52 week low of $5.93 and a 52 week high of $14.00.
Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.05. The company had revenue of $670.48 million for the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. On average, analysts expect that Aveanna Healthcare Holdings Inc. will post 0.75 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CEO Jeff Shaner sold 90,000 shares of the company's stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $1,035,000.00. Following the completion of the sale, the chief executive officer directly owned 2,561,972 shares of the company's stock, valued at $29,462,678. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Paul R. Vigano sold 2,250,000 shares of Aveanna Healthcare stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.50, for a total transaction of $25,875,000.00. Following the transaction, the insider owned 12,315,892 shares in the company, valued at approximately $141,632,758. The trade was a 15.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 79,746,745 shares of company stock worth $773,117,091. Company insiders own 5.30% of the company's stock.
About Aveanna Healthcare
(
Free Report)
Aveanna Healthcare, Inc NASDAQ: AVAH is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.
In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Aveanna Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aveanna Healthcare wasn't on the list.
While Aveanna Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
